Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs AquaVita NextGen

Two GLP-1 desks, one scoreboard. We put Trimi and AquaVita NextGen head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 176 · Grade C

AquaVita NextGen

Visit AquaVita NextGen Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 67 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make AquaVita NextGen a bad call — it's best for patients in az/ca/fl/tx/nv seeking medspa-backed glp-1 with a named medical director. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
36
Supply Reliability
89
71
Transparency
91
88
Access Breadth
89
62
Clinical Oversight
88
82
Track Record
84
73
TrimiBrief Score 89 · 67AquaVita NextGen

Price, coverage & the tracker

TrimiAquaVita NextGen
Brief Score89/100 (B+)67/100 (C)
Semaglutide$196/moFrom $375/mo (compounded)
Tirzepatide$296/moFrom $320/mo (starting dose, compounded)
CoverageAll 50 states5 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

AquaVita NextGen: New to the tracker on 1 August 2026. The published line reads From $320/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.